CR10420A - Derivados biciclicos como inhibibidores de cetp - Google Patents

Derivados biciclicos como inhibibidores de cetp

Info

Publication number
CR10420A
CR10420A CR10420A CR10420A CR10420A CR 10420 A CR10420 A CR 10420A CR 10420 A CR10420 A CR 10420A CR 10420 A CR10420 A CR 10420A CR 10420 A CR10420 A CR 10420A
Authority
CR
Costa Rica
Prior art keywords
inhibibers
cetp
present
bicycle derivatives
relates
Prior art date
Application number
CR10420A
Other languages
English (en)
Inventor
Kishida Masashi
Matsuura Naoko
Imase Hidetomo
Iwaki Yuki
Umemura Ichiro
Ohmori Osamu
Kawahara Eiji
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB0609268.8A external-priority patent/GB0609268D0/en
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of CR10420A publication Critical patent/CR10420A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

La presente invencion se refiere a novedosos compuestos de la Formula (I): o una composicion farmaceutica de los mismos, estando todas las variables definidas en el texto. La presente invencion se refiere ademas la uso de los compuestos de la presente para el tratamiento de, o demora de progreso para superar, las enfermedades en donde este involucrada la proteina de transferencia de colesteril-ester.
CR10420A 2006-05-10 2008-10-30 Derivados biciclicos como inhibibidores de cetp CR10420A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0609268.8A GB0609268D0 (en) 2006-05-10 2006-05-10 Organic compounds
US86648006P 2006-11-20 2006-11-20
US89614207P 2007-03-21 2007-03-21

Publications (1)

Publication Number Publication Date
CR10420A true CR10420A (es) 2009-02-02

Family

ID=38445602

Family Applications (1)

Application Number Title Priority Date Filing Date
CR10420A CR10420A (es) 2006-05-10 2008-10-30 Derivados biciclicos como inhibibidores de cetp

Country Status (17)

Country Link
US (2) US8232403B2 (es)
EP (1) EP2024356A1 (es)
KR (1) KR101172120B1 (es)
AR (1) AR060873A1 (es)
AU (1) AU2007247385B2 (es)
CA (1) CA2650954C (es)
CL (1) CL2007001325A1 (es)
CR (1) CR10420A (es)
EC (1) ECSP088891A (es)
GT (1) GT200800242A (es)
IL (1) IL195010A0 (es)
MA (1) MA30427B1 (es)
MX (1) MX2008014284A (es)
NO (1) NO20084912L (es)
TN (1) TNSN08444A1 (es)
TW (1) TW200813009A (es)
WO (1) WO2007128568A1 (es)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1848430T3 (da) 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
KR20080086917A (ko) * 2005-12-29 2008-09-26 노파르티스 아게 콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 억제제로서의피리디닐 아민 유도체
WO2007128568A1 (en) * 2006-05-10 2007-11-15 Novartis Ag Bicyclic derivatives as cetp inhibitors
BRPI0711447A2 (pt) * 2006-05-11 2011-11-08 Novartis Ag compostos orgánicos
US7750019B2 (en) 2006-08-11 2010-07-06 Kowa Company, Ltd. Pyrimidine compound having benzyl(pyridylmethyl)amine structure and medicament comprising the same
US7790737B2 (en) 2007-03-13 2010-09-07 Kowa Company, Ltd. Substituted pyrimidine compounds and their utility as CETP inhibitors
MX2009010962A (es) 2007-04-13 2009-12-16 Kowa Co Compuesto pirimidina novedoso que tiene estructura de dibencilamina y medicamento que comprende el mismo.
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5478508B2 (ja) 2008-11-28 2014-04-23 興和株式会社 ｔｒａｎｓ−｛４−［（アルキルアミノ）メチル］シクロヘキシル｝酢酸エステルの製造方法
EA021275B9 (ru) * 2009-09-03 2015-08-31 Байоэнердженикс Гетероциклические соединения, содержащая их фармацевтическая композиция и их применение для лечения pask-опосредованного заболевания
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
PL2729142T3 (pl) 2011-07-08 2018-10-31 Novartis Ag Sposób leczenia miażdżycy tętnic u osobników z wysokim poziomem triglicerydów
CA2845284C (en) 2011-08-18 2018-03-06 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholesteryl ester-transfer protein (cetp) inhibitors
JP6140168B2 (ja) 2011-09-27 2017-05-31 ドクター レディズ ラボラトリーズ リミテッド アテローム性動脈硬化症の処置のために有用なコレステリルエステル転送タンパク質（ｃｅｔｐ）インヒビターとしての５−ベンジルアミノメチル−６−アミノピラゾロ［３，４−ｂ］ピリジン誘導体
CA2891502A1 (en) * 2012-11-19 2014-05-22 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US20160000799A1 (en) * 2013-02-21 2016-01-07 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
US9266925B2 (en) 2013-07-25 2016-02-23 Novartis Ag Cyclic polypeptides for the treatment of heart failure
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
CA2972871A1 (en) 2015-01-23 2016-07-28 Novartis Ag Synthetic apelin fatty acid conjugates with improved half-life
US12162863B2 (en) 2018-06-12 2024-12-10 Ryvu Therapeutics S.A. Modulators of stimulator of interferon genes (STING)
IL288868B2 (en) 2019-06-12 2025-02-01 Ryvu Therapeutics S A Next generation of stimulator of interferon genes (STING) modulators
KR20260022465A (ko) * 2019-12-11 2026-02-19 리부 세라퓨틱스 에스.에이. 인터페론 유전자 자극제(sting)의 조절제인 헤테로사이클릭 화합물

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6451823B1 (en) * 1999-09-23 2002-09-17 G.D. Searle & Co. Use of substituted N-phenoxy-N-phenyl aminoalcohol compounds for inhibiting cholesteryl ester transfer protein activity
CA2420967A1 (en) * 2000-08-07 2002-02-14 Neurogen Corporation Heterocyclic compounds as ligands of the gabaa receptor
ES2277142T3 (es) 2002-08-30 2007-07-01 Japan Tobacco Inc. Compuesto de dibencilamina y su uso medicinal.
ATE552253T1 (de) 2002-11-08 2012-04-15 Novartis Int Pharm Ltd 3-substituierte-6-aryl- pyridin derivate als liganden für c5a-rezeptoren
CN1795177A (zh) 2003-03-28 2006-06-28 辉瑞产品公司 作为治疗动脉粥样硬化和肥胖症的cetp抑制剂的 1 , 2 , 4 , －取代的1，2，3，4，－四氢－和1，2二氢－喹啉以及1， 2 , 3 ， 4－四氢－喹喔啉衍生物
US7371759B2 (en) * 2003-09-25 2008-05-13 Bristol-Myers Squibb Company HMG-CoA reductase inhibitors and method
US7737295B2 (en) 2004-04-13 2010-06-15 Merck Sharp & Dohme Corp. CETP inhibitors
CA2589322A1 (en) 2004-11-23 2006-06-01 Pfizer Products Inc. Dibenzyl amine compounds and derivatives
US7668830B2 (en) 2004-11-29 2010-02-23 Nokia Corporation Access rights
DK1848430T3 (da) * 2004-12-31 2017-11-06 Dr Reddys Laboratories Ltd Nye benzylamin-derivativer som cetp-inhibitors
WO2007075194A1 (en) 2005-12-28 2007-07-05 Reddy Us Therapeutics, Inc. Selective benzylamine derivatives and their utility as cholesterol ester-transfer protein inhibitors
EP1834490A1 (en) 2005-01-06 2007-09-19 Thomson Licensing Reducing rainbow artifacts in digital light projection systems
US20100203504A1 (en) 2005-07-07 2010-08-12 Yoichi Katsumoto Substance-Information Acquisition Method Using Evanescent Light Beam, Substance-Information Measurement Apparatus, Base-Sequence Determination Method and Base-Sequence Determination Apparatus
US7573978B2 (en) 2005-07-11 2009-08-11 University Of Florida Research Foundation, Inc. Variable feathering field splitting for intensity modulated fields of large size
KR20080086917A (ko) * 2005-12-29 2008-09-26 노파르티스 아게 콜레스테릴 에스테르 전달 단백질 (ｃｅｔｐ) 억제제로서의피리디닐 아민 유도체
UY30118A1 (es) * 2006-01-31 2007-06-29 Tanabe Seiyaku Co Compueto amina trisustituido
WO2007128568A1 (en) * 2006-05-10 2007-11-15 Novartis Ag Bicyclic derivatives as cetp inhibitors
BRPI0711447A2 (pt) * 2006-05-11 2011-11-08 Novartis Ag compostos orgánicos
MX2009005249A (es) * 2006-11-15 2009-05-28 Novartis Ag Compuestos organicos.
CN101535293A (zh) * 2006-11-15 2009-09-16 诺瓦提斯公司 作为cetp抑制剂的杂环衍生物

Also Published As

Publication number Publication date
AU2007247385A1 (en) 2007-11-15
WO2007128568A1 (en) 2007-11-15
AR060873A1 (es) 2008-07-16
CA2650954A1 (en) 2007-11-15
US20120225874A1 (en) 2012-09-06
MX2008014284A (es) 2008-11-18
NO20084912L (no) 2009-02-03
IL195010A0 (en) 2009-08-03
US8410275B2 (en) 2013-04-02
KR20090017580A (ko) 2009-02-18
KR101172120B1 (ko) 2012-08-10
CL2007001325A1 (es) 2008-07-18
AU2007247385B2 (en) 2011-07-14
TW200813009A (en) 2008-03-16
US8232403B2 (en) 2012-07-31
TNSN08444A1 (en) 2010-04-14
EP2024356A1 (en) 2009-02-18
GT200800242A (es) 2009-04-29
ECSP088891A (es) 2008-12-30
CA2650954C (en) 2014-02-11
MA30427B1 (fr) 2009-05-04
US20090227580A1 (en) 2009-09-10

Similar Documents

Publication Publication Date Title
ECSP088891A (es) Derivados bicíclicos como inhibidores de cetp
EA201100969A1 (ru) Солевые формы органического соединения
CR10614A (es) Derivados heterociclicos fusionados y metodos de uso
ECSP088414A (es) Derivados de ácido bifeniloxiacético para el tratamiento de una enfermedad respiratoria
SV2011003855A (es) Heteroarilos sustituidos
CR10192A (es) Compuestos de amido y su uso como productos farmaceuticos
CR10875A (es) Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides
ECSP10010582A (es) Derivados de aminodihidrotiazina como inhibidores de bace para el tratamiento de la enfermedad de alzheimer
GT201000023A (es) Nuevos derivados de 6-trialzolopiridacina-sulfanil benzotiazol y bencimidazol, su procedimiento de preparacion, su aplicacion como medicamentos, composiciones farmaceuticas y nueva utilizacion principalmente como inhibidores de met.
EA201001555A1 (ru) Антиоксидативные модуляторы воспаления: производные олеанолевой кислоты с аминовыми и другими модификациями на с-17
BRPI0721905B8 (pt) composto inibidor de proteassoma, sua composição farmacêutica e seu uso
ECSP088765A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratamiento o prevención de diabetes
EA201170772A1 (ru) Органические соединения
ECSP109903A (es) Derivados de pirazinona y su uso en el tratamiento de enfermedades pulmonares
UY30578A1 (es) Nuevos derivados de 2,4??- y 3, 4??-bipiridina sustituidos, procedimientos para su preparacion, medicamentos conteniéndolos y aplicaciones
UY30481A1 (es) Isoxazolinas sustituidas, composiciones farmaccuticas que contienen a las mismas, metodos de preparacion y usos.
HN2011001256A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa-iv para el tratmiento o prevencion de diabetes
AR072261A1 (es) Derivados piperazin-pirazolicos, composiciones farmaceuticas que los contienen y usos de los mismos como agentes anticancerigenos.
CR10356A (es) Derivados de 4-benzilphthalazinona 2-sustituidos como antagonistas de histamina h1 y h3
CR10948A (es) Compuestos triciclicos, composiciones y procedimientos
UY30863A1 (es) Derivados de piridopirimidina, composiciones farmacéuticas conteniéndolos, procesos de preparacion y aplicaciones
MA32723B1 (fr) Derives d'anilino-pyrimidine a substitution sulfoximine en tant qu'inhibiteurs de cdk, leur preparation et leur utilisation comme medicaments
UY29223A1 (es) Ácidos fenoxiacéticos sustituidos, composiciones farmacéuticas que los contienen y procesos para su preparación
MX2020005736A (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)